Business Context and Reporting Period
CytoMed Therapeutics Ltd (Nasdaq: GDTC) is a clinical-stage biopharmaceutical company incorporated in Singapore, focused on developing allogeneic, "off-the-shelf" cell-based immunotherapies for cancer and degenerative diseases. The company operates primarily through subsidiaries in Malaysia and Singapore. This summary covers the fiscal year ended December 31, 2024.
The company has no products approved for commercial sale. Its primary activities involve research and development (R&D) of four product candidates: CTM-N2D (lead candidate, currently in Phase I clinical trial), iPSC-gdNKT, CTM-GDT, and CTM-MSC. In late 2024, the company expanded its operations by acquiring assets of a Malaysian cord blood bank, initiating a new revenue stream.
Key Financial Metrics (Year Ended Dec 31, 2024)
| Metric | 2024 (S$) | 2024 (U.S.$) | 2023 (S$) |
|---|---|---|---|
| Revenue | 69,501 | 50,872 | 0 |
| Net Loss | (2,521,861) | (1,845,894) | (4,133,170) |
| Accumulated Losses | (14,848,135) | (10,868,200) | (12,331,437) |
| Cash and Bank Balances | 4,970,367 | 3,638,096 | 8,995,067 |
| Net Cash Used in Operating Activities | (2,709,929) | (1,983,552) | (3,531,196) |
| Total Assets | 10,067,749 | 7,369,162 | 12,368,870 |
| Total Liabilities | 1,023,960 | 749,495 | 1,124,715 |
Note: U.S. dollar conversions are based on the exchange rate of S$1.3662 to U.S.$1.00 as of December 31, 2024.
Material Changes vs. Prior Period
- Revenue Generation: The company recorded its first revenue of S$69,501 in 2024, derived from private blood banking services following the acquisition of assets from Cellsafe International Sdn Bhd in Q4 2024. This contrasts with zero revenue in 2023.
- Net Loss Reduction: The net loss decreased significantly to S$2.52 million in 2024 from S$4.13 million in 2023. This improvement was driven by a reduction in "Other expenses" (primarily due to the absence of IPO-related costs in 2024) and a net gain of S$297,545 from fair value changes on warrant liabilities and currency exchange.
- Research Expenses: R&D expenses increased to S$1.91 million in 2024 from S$1.59 million in 2023, primarily due to a S$348,169 increase in clinical trial expenses associated with the ongoing ANGELICA Trial.
- Liquidity: Cash and bank balances decreased by approximately S$4.0 million year-over-year, reflecting the cash burn from operations and investing activities (including the purchase of freehold properties and a loan to a third party).
Guidance, Outlook, and Risks
Outlook and Guidance: The company expects to continue incurring losses for the foreseeable future as it advances its product pipeline. Management anticipates recruiting more patients for the ANGELICA Trial (CTM-N2D) in 2025. The company plans to submit a Phase I clinical trial dossier for CTM-MSC in the second half of 2025. While the company generated revenue from cord blood banking, it does not expect significant revenue from commercial product sales in the near term.
Key Risks and Contingencies:
- Going Concern: The company has accumulated losses of S$14.85 million and relies on additional funding to finance operations. There is substantial doubt about its ability to continue as a going concern without securing further capital.
- Capital Requirements: The company may need to raise additional funds through equity or debt financing, which could result in shareholder dilution or restrictive covenants.
- Clinical Trial Risks: Success depends on the safety and efficacy of product candidates. Delays or failures in clinical trials (e.g., ANGELICA Trial) could materially harm the business.
- Intellectual Property: The company does not own any patents and relies on licenses from ATPL (A*STAR). Termination of these licenses would severely impact operations.
- Regulatory Environment: Operations are subject to evolving regulations in Singapore and Malaysia regarding cell and gene therapy products.
Important Facts for Investor Verification
- Cash Runway: Verify the sufficiency of the S$4.97 million cash balance to fund operations through 2026, considering the high burn rate of clinical-stage biopharma companies.
- Revenue Sustainability: Assess the scalability and profitability of the new cord blood banking segment, which contributed S$69,501 in revenue in a partial quarter.
- Intellectual Property Dependencies: Review the terms of the license agreements with ATPL, specifically the commercialization milestones and the risk of termination if milestones are missed.
- Clinical Trial Progress: Monitor the enrollment and safety data of the ANGELICA Trial (CTM-N2D), as this is the lead asset and critical for future valuation.
- Related Party Transactions: Note the 20% equity stake in Landmark Medical Centre Sdn Bhd (LMC) and the related research income (S$115,277 in 2024) derived from this associate.